Literature DB >> 30051226

Traditional Chinese medicine and drug-induced anaphylaxis: data from the Beijing pharmacovigilance database.

Xiaotong Li1,2,3, Sydney Thai4, Wenchao Lu3, Shusen Sun5, Huilin Tang6, Suodi Zhai1,2, Tiansheng Wang7,8.   

Abstract

Background Traditional Chinese medicine (TCM) is one of the major triggers for drug-induced anaphylaxis (DIA). Objective We aimed to use the Beijing pharmacovigilance database (BPD) to analyze TCM-induced DIAs in Beijing, China. Setting Drug allergy case reports from the BPD provided by the Beijing Center for Adverse Drug Reaction Monitoring. Method Drug allergy cases from January 2004 to December 2014 were adjudicated. DIA triggered by TCMs were analyzed and compared with those triggered by non-TCM drugs by calculating the reported risk ratio (RRR). We also calculated the RRRs based on severe DIA and death outcomes. Main outcome measure TCMs implicated in DIAs were identified and compared with non-TCM drugs. Results TCMs accounted for 1651 (18.2%) of the total 9074 allergic cases, in which 84.4% (1393/1651) were triggered by injections. Of the TCM allergic cases, 8.5% (141) were DIAs and 7.3% (120) were severe DIAs, and three patients died from injections. The RRR between TCMs and non-TCM-induced DIAs was 0.63. When anaphylactic cases were compared between TCMs to the top four non-TCM drug triggers, RRRs were 0.73 (95% CI 0.61-0.87) for antibiotics, 0.36 (95% CI 0.29-0.44) for radiocontrast agents, 0.55 (95% CI 0.43-0.68) for chemotherapeutics, and 0.29 (95% CI 0.23-0.37) for biologics. Compared to TCM oral or topic formulations, TCM injections had higher RRRs in each of the above comparisons. Conclusion TCM was associated with a decreased risk of DIA compared to non-TCM drugs in drug allergy cases, and the risk was higher for TCM injections.

Entities:  

Keywords:  China; Drug-induced anaphylaxis; Pharmacovigilance; Traditional Chinese medicines

Mesh:

Substances:

Year:  2018        PMID: 30051226     DOI: 10.1007/s11096-018-0699-4

Source DB:  PubMed          Journal:  Int J Clin Pharm


  15 in total

1.  Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports.

Authors:  S J Evans; P C Waller; S Davis
Journal:  Pharmacoepidemiol Drug Saf       Date:  2001 Oct-Nov       Impact factor: 2.890

2.  Use of Epinephrine in Patients with Drug-Induced Anaphylaxis: An Analysis of the Beijing Pharmacovigilance Database.

Authors:  Tiansheng Wang; Xiang Ma; Yan Xing; Shusen Sun; Hua Zhang; Til Stürmer; Bin Wang; Xiaotong Li; Huilin Tang; Ligong Jiao; Suodi Zhai
Journal:  Int Arch Allergy Immunol       Date:  2017-05-16       Impact factor: 2.749

3.  Aristolochic acids and their derivatives are widely implicated in liver cancers in Taiwan and throughout Asia.

Authors:  Alvin W T Ng; Song Ling Poon; Mi Ni Huang; Jing Quan Lim; Arnoud Boot; Willie Yu; Yuka Suzuki; Saranya Thangaraju; Cedric C Y Ng; Patrick Tan; See-Tong Pang; Hao-Yi Huang; Ming-Chin Yu; Po-Huang Lee; Sen-Yung Hsieh; Alex Y Chang; Bin T Teh; Steven G Rozen
Journal:  Sci Transl Med       Date:  2017-10-18       Impact factor: 17.956

4.  Aristolochic acid-associated urothelial cancer in Taiwan.

Authors:  Chung-Hsin Chen; Kathleen G Dickman; Masaaki Moriya; Jiri Zavadil; Viktoriya S Sidorenko; Karen L Edwards; Dmitri V Gnatenko; Lin Wu; Robert J Turesky; Xue-Ru Wu; Yeong-Shiau Pu; Arthur P Grollman
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-09       Impact factor: 11.205

5.  Drug-induced anaphylaxis: a decade review of reporting to the Portuguese Pharmacovigilance Authority.

Authors:  Inês Ribeiro-Vaz; Joana Marques; Pascal Demoly; Jorge Polónia; Eva Rebelo Gomes
Journal:  Eur J Clin Pharmacol       Date:  2012-08-23       Impact factor: 2.953

6.  Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology.

Authors:  A Muraro; G Roberts; M Worm; M B Bilò; K Brockow; M Fernández Rivas; A F Santos; Z Q Zolkipli; A Bellou; K Beyer; C Bindslev-Jensen; V Cardona; A T Clark; P Demoly; A E J Dubois; A DunnGalvin; P Eigenmann; S Halken; L Harada; G Lack; M Jutel; B Niggemann; F Ruëff; F Timmermans; B J Vlieg-Boerstra; T Werfel; S Dhami; S Panesar; C A Akdis; A Sheikh
Journal:  Allergy       Date:  2014-06-09       Impact factor: 13.146

7.  Clinical features and treatment of pediatric patients with drug-induced anaphylaxis: a study based on pharmacovigilance data.

Authors:  Yan Xing; Hua Zhang; Shusen Sun; Xiang Ma; Roy A Pleasants; Huilin Tang; Hangci Zheng; Suodi Zhai; Tiansheng Wang
Journal:  Eur J Pediatr       Date:  2017-11-22       Impact factor: 3.183

8.  Drug-induced anaphylaxis in China: a 10 year retrospective analysis of the Beijing Pharmacovigilance Database.

Authors:  Ying Zhao; Shusen Sun; Xiaotong Li; Xiang Ma; Huilin Tang; Lulu Sun; Suodi Zhai; Tiansheng Wang
Journal:  Int J Clin Pharm       Date:  2017-10-31

Review 9.  Novel statistical tools for monitoring the safety of marketed drugs.

Authors:  J S Almenoff; E N Pattishall; T G Gibbs; W DuMouchel; S J W Evans; N Yuen
Journal:  Clin Pharmacol Ther       Date:  2007-05-30       Impact factor: 6.875

10.  2015 update of the evidence base: World Allergy Organization anaphylaxis guidelines.

Authors:  F Estelle R Simons; Motohiro Ebisawa; Mario Sanchez-Borges; Bernard Y Thong; Margitta Worm; Luciana Kase Tanno; Richard F Lockey; Yehia M El-Gamal; Simon Ga Brown; Hae-Sim Park; Aziz Sheikh
Journal:  World Allergy Organ J       Date:  2015-10-28       Impact factor: 4.084

View more
  3 in total

Review 1.  Overuse of intravenous infusions in China: focusing on management platform and cultural problems.

Authors:  Shuangshuang Zeng; Dong Wang; Wanli Liu; Yuanliang Yan; Minwen Zhu; Zhicheng Gong; Shusen Sun
Journal:  Int J Clin Pharm       Date:  2019-08-30

2.  Overview of this issue: pharmacovigilance, what is new?

Authors:  Linda Gore Martin; Yolande Hanssens; Vibhu Paudyal
Journal:  Int J Clin Pharm       Date:  2018-08

3.  Chinese Medicine for Chronic Obstructive Pulmonary Disease: A Pilot Study on Patient Preferences.

Authors:  Shaonan Liu; Jiaqi Lai; Lei Wu; Xinfeng Guo
Journal:  Patient Prefer Adherence       Date:  2021-07-08       Impact factor: 2.711

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.